CD274 and neoplasm: For positive PD-L1 assessments across tumor types, the maximum ORR was 72.7% (RNA-seq) and 55.6% (IHC), 28.6% (RNA-seq) and 42.1% (IHC), and 33.3% (RNA-seq) and 40% (IHC) for melanoma, NSCLC and RCC, respectively.